Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 7/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | PRKACA | P17612 | 2/20 | 0.45 |
| ▸ | PRKACG | P22612 | 2/20 | 0.45 |
| ▸ | PRKACB | P22694 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | STK4 | Q13043 | 1/20 | 0.44 |
| ▸ | STK3 | Q13188 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489449 | 0.89 | AKT1 (0.46) | AKT1LIMK1ROCK2PRKACAROCK1 | |
| SCHEMBL3492018 | 0.89 | AKT1 (0.50) | AKT1STK4STK3 | |
| SCHEMBL3489823 | 0.82 | AKT2 (0.43) | — | |
| SCHEMBL3489867 | 0.81 | AKT2 (0.60) | AKT1 | |
| SCHEMBL3489391 | 0.81 | LMNA (0.37) | AKT1LIMK2 | |
| SCHEMBL3491281 | 0.80 | AKT1 (0.42) | AKT1LIMK1LIMK2ROCK2ROCK1 | |
| SCHEMBL3492153 | 0.73 | LRRK2 (0.49) | LIMK1LIMK2ROCK2PRKACAPRKACG | |
| SCHEMBL3492023 | 0.73 | AKT2 (0.52) | AKT1ROCK2 | |
| SCHEMBL3490576 | 0.72 | AKT2 (0.56) | AKT1ROCK2 | |
| SCHEMBL27782474 | 0.72 | LIMK1 (0.62) | AKT1LIMK1LIMK2ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2125805-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | AKT1 18/4885LIMK1 1891/4885LIMK2 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.